In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.
In April 2019, Finland reported false-negative or equivocal results in patients tested for Chlamydia trachomatis (CT) using Aptima Combo 2 Assay (Hologic) (AC2).
An ECDC country visit team conducted an assessment mission during the period 12–16 March 2018 to discuss antimicrobial resistance (AMR) issues in Norway. The overall objective of the mission was to provide an observation-based assessment of the situation in Norway regarding prevention and control of AMR through prudent use of antibiotics and infection control.
Illnesses caused by infectious diseases are common in children in schools or other childcare settings. Currently there is no common EU approach to the control of communicable diseases in schools or other childcare settings, and existing information is uncertain.
This risk assessment was triggered by two cases of paralytic poliomyelitis in children, caused by circulating vaccine-derived poliovirus type 1 (cVDPV1) in Ukraine during June and July 2015.
This rapid risk assessment considers the risk to the EU of an outbreak of invasive meningococcal disease in the UK and Sweden associated with the 23rd World Scout Jamboree in Japan.
ECDC and EFSA have assessed the risk to the EU/EEA posed by a fatal human case of Bacillus anthracis infection in Bulgaria and concluded that this event represents a negligible risk to other EU/EEA countries.
This rapid risk assessment examines the implications of the temporary recommendations for EU Member States and assesses whether the developments leading to the declaration of a PHEIC represent an increased risk of WPV importation to Member States of the European Union.
The confirmed circulation of wild-type poliovirus (WPV) in Israel and the outbreak of poliomyelitis in Syria mean that there is a high risk the disease will be reintroduced into the EU/EEA.